Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Therapy, By Diagnosis, By Region, And Segment Forecasts, 2019 - 2026

Published: May, 2019 | Pages: 100 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global hemoglobinopathies market size is expected to reach USD 12.6 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 10.2% during the forecast period.

Rising prevalence of hemoglobin disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E is estimated to be a high impact rendering driver for the market. According to the World Health Organization (WHO), hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant hemoglobin variation.

Prevalence of hemoglobinopathies is high in low-income countries from regions, such as Sub-Saharan region and South-east Asia. 85% of the affected population in U.S. and Europe has ancestral base in these regions.

Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Sickle Cell Disease Coalition (SCDC) was founded by The American Society of Hematology (ASH) in 2016 to promote awareness for the condition and enhance outcomes for individuals.

Insufficient healthcare infrastructure and low levels of disease diagnosis and treatments are some of the key factors contributing to the increase in target population in low-income regions such as South-east Asia, Mediterranean basin, and Africa.

North America led the overall hemoglobinopathies market in terms of revenue in 2018. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing, are the factors attributed to the growth.

Asia Pacific is expected to witness lucrative growth over the forecast period owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives for hemoglobinopathies is likely to further boost the growth.

Further key findings from the report suggest:

• SCD segment held the largest market share in 2018 owing to rising prevalence of sickle cell disease and presence of strong product pipeline such as LentiGlobin

• Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. Increasing awareness coupled with rising government programs is anticipated to enhance the usage rates for diagnostic tests pertaining to SCD

• Pre-implant genetic diagnosis is estimated to witness lucrative CAGR of over 8.0% during the forecast period owing to rising awareness levels among the population and increasing healthcare expenditure

• Blood transfusion was the largest therapy segment for hemoglobinopathies, owing to high acceptance of this treatment option and significant success rate

• Key market players include Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation

 Table of Contents

Chapter 1. Methodology and Scope
                     1.1. Market segmentation & scope
                     1.2. Market definition
                     1.3. Information procurement
                          1.3.1. Purchased database
                          1.3.2. GVR’s internal database
                          1.3.3. Secondary sources & third party perspectives
                          1.3.4. Primary research
                     1.4. Information analysis
                          1.4.1. Data analysis models
                     1.5. Market formulation & data visualization
                     1.6. Data validation & publishing

Chapter 2. Executive Summary
                     2.1. Market Outlook 
                     2.2. Segment Outlook 
                     2.3. Competitive Insights

Chapter 3. Global Hemoglobinopathies Market Variables, Trends & Scope
                     3.1. Penetration & Growth Prospect Mapping
                     3.2. Epidemiology Assessment of Hemoglobinopathies
                     3.3. Market Dynamics
                          3.3.1. Market Driver Analysis
                          3.3.2. Market Restraint Analysis
                     3.4. Hemoglobinopathies Market Analysis Tools
                          3.4.1. Industry Analysis - Porter’s
                               3.4.1.1. Supplier Power: Moderate 
                               3.4.1.2. Buyer Power: Moderate
                               3.4.1.3. Substitution Threat: Low
                               3.4.1.4. Threat from new entrant: High
                               3.4.1.5. Competitive rivalry: High 
                     3.5. PESTEL Analysis
                          3.5.1. Political Landscape
                          3.5.2. Environmental Landscape
                          3.5.3. Social Landscape
                          3.5.4. Technology Landscape
                          3.5.5. Legal Landscape

Chapter 4. Hemoglobinopathies Market: Type Estimates & Trend Analysis 
                     4.1. Definitions & Scope 
                     4.2. Type market share analysis, 2018 & 2026
                     4.3. Type Dashboard 
                     4.4. Global Hemoglobinopathies Market, by Type, 2014 to 2026
                     4.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                     4.6. Thalassemia
                          4.6.1. Thalassemia market, 2014 - 2026 (USD Million)
                          4.6.2. Alpha thalassemia 
                               4.6.2.1. Alpha thalassemia market, 2014 - 2026 (USD Million)
                          4.6.3. Beta thalassemia
                               4.6.3.1. Beta thalassemia market, 2014 - 2026 (USD Million)
                     4.7. Sickle Cell Disease (SCD)
                          4.7.1. Sickle Cell Disease (SCD) market, 2014 - 2026 (USD Million)
                     4.8. Other Hb Variants
                          4.8.1. Other Hb Variants market, 2014 - 2026 (USD Million)

Chapter 5. Hemoglobinopathies Market: Therapy Estimates & Trend Analysis 
                     5.1. Definitions & Scope 
                     5.2. Therapy market share analysis, 2018 & 2026
                     5.3. Therapy Dashboard 
                     5.4. Global Hemoglobinopathies Market, by Therapy, 2014 to 2026
                     5.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                     5.6. Thalassemia therapy
                          5.6.1. Thalassemia therapy market, 2014 - 2026 (USD Million)
                          5.6.2. Alpha thalassemia therapy
                               5.6.2.1. Alpha thalassemia therapy market, 2014 - 2026 (USD Million)
                          5.6.3. Beta thalassemia therapy
                               5.6.3.1. Beta thalassemia therapy market, 2014 - 2026 (USD Million)
                     5.7. Sickle Cell Disease (SCD) Therapy
                          5.7.1. Sickle Cell Disease (SCD) therapy market, 2014 - 2026 (USD Million)
                     5.8. Other Hb Variants Therapy
                          5.8.1. Other Hb Variants therapy market, 2014 - 2026 (USD Million)

Chapter 6. Hemoglobinopathies Market: Diagnosis Estimates & Trend Analysis 
                     6.1. Definitions & Scope 
                     6.2. Diagnosis market share analysis, 2018 & 2026
                     6.3. Diagnosis Dashboard 
                     6.4. Global Hemoglobinopathies Market, by Diagnosis, 2014 to 2026
                     6.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                     6.6. Thalassemia diagnosis
                          6.6.1. Thalassemia diagnosis market, 2014 - 2026 (USD Million)
                          6.6.2. Alpha thalassemia diagnosis
                               6.6.2.1. Alpha thalassemia diagnosis market, 2014 - 2026 (USD Million)
                          6.6.3. Beta thalassemia diagnosis
                               6.6.3.1. Beta thalassemia diagnosis market, 2014 - 2026 (USD Million)
                     6.7. Sickle Cell Disease (SCD) diagnosis
                          6.7.1. Sickle Cell Disease (SCD) diagnosis market, 2014 - 2026 (USD Million)
                     6.8. Other Hb Variants diagnosis
                          6.8.1. Other Hb Variants diagnosis market, 2014 - 2026 (USD Million)

Chapter 7. Hemoglobinopathies Market: Regional Estimates & Trend analysis, by Type, Therapy & Diagnosis
                     7.1. Regional Market Snapshot 
                     7.2. Regional Market Share and Leading Players, 2018
                          7.2.1. North America
                          7.2.2. Europe
                          7.2.3. Asia Pacific
                          7.2.4. Latin America
                          7.2.5. Middle East & Africa
                     7.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
                          7.3.1. North America 
                          7.3.2. Europe
                          7.3.3. Asia Pacific
                          7.3.4. Latin America
                          7.3.5. Middle East & Africa
                     7.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
                     7.5. North America
                          7.5.1. North America hemoglobinopathies market, 2014 - 2026 (USD Million) 
                          7.5.2. U.S.
                               7.5.2.1. U.S. hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.5.3. Canada
                               7.5.3.1. Canada hemoglobinopathies market, 2014 - 2026 (USD Million)
                     7.6. Europe
                          7.6.1. Europe hemoglobinopathies market, 2014 - 2026 (USD Million) 
                          7.6.2. U.K.
                               7.6.2.1. U.K. hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.6.3. Germany
                               7.6.3.1. Germany hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.6.4. Spain
                               7.6.4.1. Spain. hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.6.5. France
                               7.6.5.1. France hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.6.6. Italy
                               7.6.6.1. Italy hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.6.7. Russia
                               7.6.7.1. Russia hemoglobinopathies market, 2014 - 2026 (USD Million)
                     7.7. Asia Pacific
                          7.7.1. Asia Pacific hemoglobinopathies market, 2014 - 2026 (USD Million) 
                          7.7.2. China
                               7.7.2.1. China hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.7.3. Japan
                               7.7.3.1. Japan hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.7.4. India
                               7.7.4.1. India hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.7.5. South Korea
                               7.7.5.1. South Korea hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.7.6. Singapore
                               7.7.6.1. Singapore hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.7.7. Australia
                               7.7.7.1. Australia hemoglobinopathies market, 2014 - 2026 (USD Million)
                     7.8. Latin America
                          7.8.1. Latin America hemoglobinopathies market, 2014 - 2026 (USD Million) 
                          7.8.2. Brazil
                               7.8.2.1. Brazil hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.8.3. Mexico
                               7.8.3.1. Mexico hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.8.4. Argentina
                               7.8.4.1. Argentina hemoglobinopathies market, 2014 - 2026 (USD Million)
                     7.9. MEA
                          7.9.1. MEA hemoglobinopathies market, 2014 - 2026 (USD Million) 
                          7.9.2. South Africa
                               7.9.2.1. South Africa hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.9.3. Saudi Arabia
                               7.9.3.1. Saudi Arabia hemoglobinopathies market, 2014 - 2026 (USD Million)
                          7.9.4. UAE
                               7.9.4.1. UAE hemoglobinopathies market, 2014 - 2026 (USD Million)

Chapter 8. Company Profiles
                     8.1. Strategic Framework
                          8.1.1. Gamida Cell
                               8.1.1.1. Company overview
                               8.1.1.2. Financial framework
                               8.1.1.3. Product benchmarking
                               8.1.1.4. Strategic initiatives
                          8.1.2. Alnylam Pharmaceuticals, Inc. 
                               8.1.2.1. Company overview
                               8.1.2.2. Financial framework
                               8.1.2.3. Product benchmarking
                               8.1.2.4. Strategic initiatives
                          8.1.3. Sanofi
                               8.1.3.1. Company overview
                               8.1.3.2. Financial framework
                               8.1.3.3. Product benchmarking
                               8.1.3.4. Strategic initiatives
                          8.1.4. Sangamo Therapeutics, Inc.
                               8.1.4.1. Company overview
                               8.1.4.2. Financial framework
                               8.1.4.3. Product benchmarking
                               8.1.4.4. Strategic initiatives
                          8.1.5. Bluebird bio, Inc.
                               8.1.5.1. Company overview
                               8.1.5.2. Financial framework
                               8.1.5.3. Product benchmarking
                               8.1.5.4. Strategic initiatives
                          8.1.6. Global Blood Therapeutics Inc.
                               8.1.6.1. Company overview
                               8.1.6.2. Financial framework
                               8.1.6.3. Product benchmarking
                               8.1.6.4. Strategic initiatives
                          8.1.7. Emmaus Life Sciences, Inc.
                               8.1.7.1. Company overview
                               8.1.7.2. Financial framework
                               8.1.7.3. Product benchmarking
                               8.1.7.4. Strategic initiatives
                          8.1.8. Prolong Pharmaceuticals, LLC
                               8.1.8.1. Company overview
                               8.1.8.2. Financial framework
                               8.1.8.3. Product benchmarking
                               8.1.8.4. Strategic initiatives
                          8.1.9. Celgene Corporation
                               8.1.9.1. Company overview
                               8.1.9.2. Financial framework
                               8.1.9.3. Product benchmarking
                               8.1.9.4. Strategic initiatives

List of Tables

TABLE 1 List of Abbreviation
TABLE 2 North America Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 3 North America Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 4 North America Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 5 North America Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 6 North America Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 7 North America Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 8 North America Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 9 U.S. Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 10 U.S. Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 11 U.S. Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 12 U.S. Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 13 U.S. Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 14 U.S. Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 15 U.S. Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 16 Canada Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 17 Canada Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 18 Canada Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 19 Canada Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 20 Canada Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 21 Canada Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 22 Canada Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 23 Europe Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 24 Europe Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 25 Europe Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 26 Europe Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 27 Europe Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 28 Europe Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 29 Europe Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 30 Germany Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 31 Germany Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 32 Germany Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 33 Germany Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 34 Germany Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 35 Germany Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 36 Germany Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 37 France Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 38 France Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 39 France Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 40 France Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 41 France Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 42 France Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 43 France Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 44 U.K. Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 45 U.K. Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 46 U.K. Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 47 U.K. Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 48 U.K. Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 49 U.K. Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 50 U.K. Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 51 Italy Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 52 Italy Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 53 Italy Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 54 Italy Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 55 Italy Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 56 Italy Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 57 Italy Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 58 Spain Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 59 Spain Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 60 Spain Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 61 Spain Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 62 Spain Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 63 Spain Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 64 Spain Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 65 Russia Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 66 Russia Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 67 Russia Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 68 Russia Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 69 Russia Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 70 Russia Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 71 Russia Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 72 Asia Pacific Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 73 Asia Pacific Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 74 Asia Pacific Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 75 Asia Pacific Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 76 Asia Pacific Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 77 Asia Pacific Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 78 Asia Pacific Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 79 Japan Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 80 Japan Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 81 Japan Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 82 Japan Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 83 Japan Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 84 Japan Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 85 Japan Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 86 China Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 87 China Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 88 China Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 89 China Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 90 China Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 91 China Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 92 China Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 93 India Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 94 India Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 95 India Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 96 India Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 97 India Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 98 India Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 99 India Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 100 South Korea Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 101 South Korea Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 102 South Korea Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 103 South Korea Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 104 South Korea Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 105 South Korea Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 106 South Korea Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 107 Australia Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 108 Australia Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 109 Australia Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 110 Australia Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 111 Australia Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 112 Australia Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 113 Australia Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 114 Singapore Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 115 Singapore Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 116 Singapore Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 117 Singapore Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 118 Singapore Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 119 Singapore Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 120 Singapore Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 121 Latin America Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 122 Latin America Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 123 Latin America Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 124 Latin America Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 125 Latin America Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 126 Latin America Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 127 Latin America Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 128 Brazil Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 129 Brazil Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 130 Brazil Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 131 Brazil Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 132 Brazil Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 133 Brazil Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 134 Brazil Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 135 Mexico Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 136 Mexico Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 137 Mexico Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 138 Mexico Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 139 Mexico Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 140 Mexico Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 141 Mexico Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 142 Argentina Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 143 Argentina Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 144 Argentina Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 145 Argentina Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 146 Argentina Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 147 Argentina Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 148 Argentina Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 149 MEA Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 150 MEA Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 151 MEA Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 152 MEA Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 153 MEA Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 154 MEA Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 155 MEA Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 156 South Africa Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 157 South Africa Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 158 South Africa Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 159 South Africa Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 160 South Africa Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 161 South Africa Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 162 South Africa Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 163 Saudi Arabia Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 164 Saudi Arabia Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 165 Saudi Arabia Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 166 Saudi Arabia Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 167 Saudi Arabia Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 168 Saudi Arabia Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 169 Saudi Arabia Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)
TABLE 170 UAE Hemoglobinopathies Market, by Type, 2014 - 2026 (USD Million)
TABLE 171 UAE Hemoglobinopathies Market, by Thalassemia Therapy, 2014 - 2026 (USD Million)
TABLE 172 UAE Hemoglobinopathies Market, by Thalassemia Diagnosis, 2014 - 2026 (USD Million)
TABLE 173 UAE Hemoglobinopathies Market, by Sickle Cell Disease Therapy, 2014 - 2026 (USD Million)
TABLE 174 UAE Hemoglobinopathies Market, by Sickle Cell Disease Diagnosis, 2014 - 2026 (USD Million)
TABLE 175 UAE Hemoglobinopathies Market, by Other Hb Variants Therapy, 2014 - 2026 (USD Million)
TABLE 176 UAE Hemoglobinopathies Market, by Other Hb Variants Diagnosis, 2014 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global hemoglobinopathies- Key market driver analysis
FIG. 7 Global hemoglobinopathies market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Global hemoglobinopathies market - Porter’s analysis
FIG. 10 Global hemoglobinopathies market - PESTEL analysis
FIG. 11 Global hemoglobinopathies market: Type outlook key takeaways
FIG. 12 Global hemoglobinopathies market: Type movement analysis
FIG. 13 Type market estimates, 2014 - 2026 (USD Million)
FIG. 14 Thalassemia market estimates, 2014 - 2026 (USD Million)
FIG. 15 Sickle cell disease market estimates, 2014 - 2026 (USD Million)
FIG. 16 Other Hb variants market estimates, 2014 - 2026 (USD Million)
FIG. 17 Global hemoglobinopathies market: Therapy outlook key takeaways
FIG. 18 Global hemoglobinopathies market: Therapy movement analysis
FIG. 19 Global hemoglobinopathies market: Diagnosis outlook key takeaways
FIG. 20 Global hemoglobinopathies market: Diagnosis movement analysis
FIG. 21 Global hemoglobinopathies regional market place: Key takeaways
FIG. 22 Global hemoglobinopathies market: Regional movement analysis
FIG. 23 North America hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 24 U.S. hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 25 Canada hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 26 Europe hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 27 Germany hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 28 France hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 29 U.K hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 30 Italy hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 31 Spain hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 32 Russia hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 33 Asia Pacific hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 34 Japan hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 35 China hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 36 India hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 37 South Korea hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 38 Australia hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 39 Singapore hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 40 Latin America hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 41 Brazil hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 42 Mexico hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 43 Argentina hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 44 MEA hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 45 South Africa hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 46 Saudi Arabia hemoglobinopathies market, 2014 - 2026 (USD Million)
FIG. 47 UAE hemoglobinopathies market, 2014 - 2026 (USD Million)